United States · Wires & real time · Business Wire

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

Published by Business Wire · United States 13 h ago

PharmaEssentia’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has secured approvals for essential thrombocythemia (ET) in Taiwan, Japan, the ...

Read the full article on Business Wire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.businesswire.com)

Also worth reading

PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lumentum Holdings Inc. (NASDAQ: LITE)

Associated Press (Business)

8 innovative gifts meant to change up how we drive, cook, sleep and more

Dow Jones Newswires

Rethinking AI in Enterprise Intelligence

MT Newswires

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

Share

Also worth reading

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lumentum Holdings Inc. (NASDAQ: LITE)

8 innovative gifts meant to change up how we drive, cook, sleep and more

Rethinking AI in Enterprise Intelligence

Global Financial News from MT Newswires Now Live in Microsoft Copilot